Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions.

Article Details

Citation

Uesawa Y, Takeuchi T, Mohri K

Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions.

Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.

PubMed ID
22039822 [ View in PubMed
]
Abstract

Concomitant consumption of grapefruit juice (GFJ) causes increases in the plasma concentration of a variety of drugs due to inhibition of intestinal CYP3A enzyme. Dihydropyridine calcium channel blockers belong to the category of drugs that are most prone to undergo such interaction. Increases in area under the plasma concentration-time curve (AUC) due to GFJ differ greatly depending on the dihydropyridine administered. Therefore, a meta-analysis of each dihydropyridine was performed based on available literature. The criteria for using a publication were: subjects were healthy adults, dihydropyridines were taken with GFJ concomitantly or within one hour after intake of the juice, and the control group administered water in place of GFJ. In these studies, the investigations on GFJ interactions with 13 dihydropyridines such as amlodipine, azelnidipine, benidipine, cilnidipine, efonidipine, felodipine, manidipine, nicardipine, nifedipine, nimodipine, nisoldipine, nitrendipine and pranidipine were reported. As a result of meta-analyses, statistically significant interactions were not identified in amlodipine. Next, correlation analyses between the physicochemical properties and interaction strengths of the dihydropyridines were performed to clarify the cause of the variation in the strengths that was dependent on the dihydropyridine. LogP, molecular weight, topological polar surface area (tPSA), molar refractivity, water diffusion, molecular volume, molecular density, molecular polarizability, and refractive index were calculated from the chemical structures. The interaction strength was defined as the logarithmic values of the increasing AUC ratio. The correlation analyses indicated a relationship of logP and tPSA with the interaction strengths. These findings suggest that the wide difference in the potency of interaction of each dihydropyridine may be explained by the presence of hydrophobic and electrostatic interactions between dihydropyridines and intestinal CYP3A enzyme.

DrugBank Data that Cites this Article

Drug Enzymes
DrugEnzymeKindOrganismPharmacological ActionActions
AgmatineCytochrome P450 3A4ProteinHumans
No
Substrate
Details
BencyclaneCytochrome P450 3A4ProteinHumans
No
Substrate
Details
BepridilCytochrome P450 3A4ProteinHumans
No
Substrate
Details
CarboxyamidotriazoleCytochrome P450 3A4ProteinHumans
No
Substrate
Details
CaroverineCytochrome P450 3A4ProteinHumans
No
Substrate
Details
CilnidipineCytochrome P450 3A4ProteinHumans
No
Substrate
Details
CinnarizineCytochrome P450 3A4ProteinHumans
No
Substrate
Details
ClevidipineCytochrome P450 3A4ProteinHumans
Unknown
Substrate
Inhibitor
Inducer
Details
CyclandelateCytochrome P450 3A4ProteinHumans
No
Substrate
Details
DarodipineCytochrome P450 3A4ProteinHumans
No
Substrate
Details
DexniguldipineCytochrome P450 3A4ProteinHumans
No
Substrate
Details
DexverapamilCytochrome P450 3A4ProteinHumans
No
Substrate
Details
DotarizineCytochrome P450 3A4ProteinHumans
No
Substrate
Details
EfonidipineCytochrome P450 3A4ProteinHumans
Unknown
Substrate
Inhibitor
Details
EmopamilCytochrome P450 3A4ProteinHumans
No
Substrate
Details
EperisoneCytochrome P450 3A4ProteinHumans
No
Substrate
Details
FendilineCytochrome P450 3A4ProteinHumans
No
Substrate
Details
Fish oilCytochrome P450 3A4ProteinHumans
No
Substrate
Details
FlunarizineCytochrome P450 3A4ProteinHumans
No
Substrate
Details
FluspirileneCytochrome P450 3A4ProteinHumans
No
Substrate
Details
GallopamilCytochrome P450 3A4ProteinHumans
No
Substrate
Details
LevomentholCytochrome P450 3A4ProteinHumans
No
Substrate
Details
LidoflazineCytochrome P450 3A4ProteinHumans
No
Substrate
Details
LomerizineCytochrome P450 3A4ProteinHumans
No
Substrate
Details
NaftopidilCytochrome P450 3A4ProteinHumans
No
Substrate
Details
NiguldipineCytochrome P450 3A4ProteinHumans
No
Substrate
Details
NiludipineCytochrome P450 3A4ProteinHumans
No
Substrate
Details
NimesulideCytochrome P450 3A4ProteinHumans
No
Substrate
Details
NylidrinCytochrome P450 3A4ProteinHumans
No
Substrate
Details
OtiloniumCytochrome P450 3A4ProteinHumans
No
Substrate
Details
PenfluridolCytochrome P450 3A4ProteinHumans
No
Substrate
Details
PinaveriumCytochrome P450 3A4ProteinHumans
No
Substrate
Details
PrenylamineCytochrome P450 3A4ProteinHumans
No
Substrate
Details
SeletracetamCytochrome P450 3A4ProteinHumans
No
Substrate
Details
TerodilineCytochrome P450 3A4ProteinHumans
No
Substrate
Details
TetrahydropalmatineCytochrome P450 3A4ProteinHumans
No
Substrate
Details
TetrandrineCytochrome P450 3A4ProteinHumans
No
Substrate
Details
Tolfenamic acidCytochrome P450 3A4ProteinHumans
No
Substrate
Details
TranilastCytochrome P450 3A4ProteinHumans
No
Substrate
Details
TrimebutineCytochrome P450 3A4ProteinHumans
No
Substrate
Details
VinpocetineCytochrome P450 3A4ProteinHumans
No
Substrate
Details
WIN 55212-2Cytochrome P450 3A4ProteinHumans
No
Substrate
Inhibitor
Details